Reinforcing the Roles of Biologic Therapy and Interprofessional Care in Improving Patient Outcomes (1 of 3)

Program Overview

Asthma is a heterogeneous disease involving multiple inflammatory pathways. While many patients can be successfully treated, others suffer from severe or difficult-to-control disease, compounded by multiple atopic conditions, and a poor quality of life. In this interprofessional panel, experts will discuss the different phenotypes and endotypes of asthma, how they affect therapy, the role of biologics in the treatment of severe or uncontrolled asthma, impact comorbid atopy can have on management and quality of life, and how we can work together as a healthcare team to manage severe and difficult-to-treat asthma.

0.25 CE Credit(s)

Expires: July 24, 2023

Target Audience

This activity is intended for allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Differentiate between phenotypes in patients with asthma according to pathogenic mechanisms and biomarkers
Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma

Activity Faculty

Michael E. Wechsler, MD, MMSc

Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

David M. Lang, MD

Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH

Rachel DeCosta, MSN, FNP-C

Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO

Supporter Statement

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Provider Statement

This activity is provided by RMEI Medical Education, LLC

Disclosure of Financial Relationships

Faculty

Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

Featured RMEI CE Activities